<DOC>
	<DOCNO>NCT02387957</DOCNO>
	<brief_summary>To evaluate safety intravitreal ( IVT ) Fovista® administer combination anti-VEGF therapy .</brief_summary>
	<brief_title>An 18 Month Phase 2a Open Label , Randomized Study Avastin® , Lucentis® , Eylea® ( Anti-VEGF Therapy ) Administered Combination With Fovista® ( Anti-PDGF BB Pegylated Aptamer )</brief_title>
	<detailed_description>60 subject randomize 1:1:1 treated IVT Fovista® 1.5 mg/eye combination anti-VEGF therapy follow : - Avastin® 1.25 mg/eye ( 20 subject ) - Lucentis® 0.5 mg/eye ( 20 subject ) - Eylea® 2.0 mg/eye ( 20 subject ) Subjects stratified lesion size ( ≤2 DA vs. &gt; 2 DA ) . Subjects treat `` combination therapy '' IVT Fovista® IVT anti-VEGF therapy every month first 5 month ( Day 1 , Months 1,2,3,4 ) , follow Q12W ( every 12 week ) administration ( Months 7,10 , 13 , 16 ) , total 18 month . When administer , IVT Fovista® give first , follow IVT anti-VEGF ( day ) .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Subjects either gender age ≥ 50 year . Active subfoveal choroidal neovascularization ( CNV ) due AMD . Any intraocular surgery thermal laser within three ( 3 ) month trial entry . Any prior thermal laser macular region , regardless indication . Subjects subfoveal scar subfoveal atrophy Any ocular periocular infection past twelve ( 12 ) week . History follow condition procedure study eye : Rhegmatogenous retinal detachment , par plana vitrectomy , filter surgery ( e.g . trabeculectomy ) , glaucoma drainage device , corneal transplant .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Wet AMD</keyword>
	<keyword>subfoveal choroidal neovascularization</keyword>
	<keyword>Fovista®</keyword>
	<keyword>Avastin®</keyword>
	<keyword>Lucentis®</keyword>
	<keyword>Eylea®</keyword>
</DOC>